In Europe they have a restrictive regime in patent extensions, which makes it difficult to enter the market. Where they have a system that's better than ours is our patent linkage system. They do not face that.
So in Canada we cannot get our approval from Health Canada until we demonstrate we've addressed a whole series of patents. That leads, as I said, to an excessive amount of litigation in Canada.